These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

97 related articles for article (PubMed ID: 8030169)

  • 41. Distribution of estramustine-binding protein during postnatal development of rat brain.
    Karlsson AE; Bergenheim AT; Brännström T; Hedman H; Henriksson R
    Histochem Cell Biol; 2001 May; 115(5):397-401. PubMed ID: 11449887
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Radioimmunoassay of tissue steroids in adenocarcinoma of the prostate.
    Belis JA; Tarry WF
    Cancer; 1981 Dec; 48(11):2416-9. PubMed ID: 7296491
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Oral estramustine therapy in serum chromogranin A-positive stage D3 prostate cancer patients.
    Zaky Ahel M; Kovacic K; Kraljic I; Tarle M
    Anticancer Res; 2001; 21(2B):1475-9. PubMed ID: 11396235
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Purification of 45 KDa estramustine binding protein (EMBP) and preparation of its antibody.
    Yuasa H; Yamanaka H; Imai K; Mashimo T; Kohno H
    Hinyokika Kiyo; 1990 Feb; 36(2):121-5. PubMed ID: 2343804
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Estramustine binding in rat, baboon and human prostate measured by high pressure liquid chromatography.
    Kirdani RY; Corrales JJ; Høisaeter PA; Karr JP; Murphy GP; Sandberg AA
    Steroids; 1981 May; 37(5):471-84. PubMed ID: 7256814
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Expression of metallopanstimulin and oncogenesis in human prostatic carcinoma.
    Fernandez-Pol JA; Fletcher JW; Hamilton PD; Klos DJ
    Anticancer Res; 1997; 17(3A):1519-30. PubMed ID: 9179190
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Expression of estramustine-binding protein in ependymomas and in human and developing rat ependymal cells.
    Bergenheim AT; Hartman M; Bergh J; Ridderheim PA; Henriksson R
    J Neurooncol; 1994; 22(1):45-53. PubMed ID: 7714550
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Estramustine-binding protein in meningioma.
    Karlsson AE; Bergenheim AT; Björk P; Henriksson R
    Acta Neuropathol; 1999 Aug; 98(2):135-40. PubMed ID: 10442552
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Concentration of the endogenous antiandrogen epitestosterone and androgenic C19-steroids in hyperplastic prostatic tissue.
    Hill M; Hampl R; Petrík R; Stárka L
    Prostate; 1996 Jun; 28(6):347-51. PubMed ID: 8650070
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Effect of dutasteride on intraprostatic androgen levels in men with benign prostatic hyperplasia or prostate cancer.
    Rittmaster R; Hahn RG; Ray P; Shannon JB; Wurzel R
    Urology; 2008 Oct; 72(4):808-12. PubMed ID: 18718641
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Three-month treatment with a long-acting gonadotropin-releasing hormone agonist of patients with benign prostatic hyperplasia: effects on tissue androgen concentration, 5 alpha-reductase activity and androgen receptor content.
    Forti G; Salerno R; Moneti G; Zoppi S; Fiorelli G; Marinoni T; Natali A; Costantini A; Serio M; Martini L
    J Clin Endocrinol Metab; 1989 Feb; 68(2):461-8. PubMed ID: 2465302
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Hormone regulation of human prostate in organ culture.
    Nevalainen MT; Härkönen PL; Valve EM; Ping W; Nurmi M; Martikainen PM
    Cancer Res; 1993 Nov; 53(21):5199-207. PubMed ID: 7693334
    [TBL] [Abstract][Full Text] [Related]  

  • 53. [What is safe in the therapy of advanced prostatic cancer?].
    Gropp C; Burk K
    Internist (Berl); 1985 Dec; 26(12):765-70. PubMed ID: 3936819
    [No Abstract]   [Full Text] [Related]  

  • 54. Study on high molecular weight androgen binding protein in submandibular gland of rat.
    Tarui M
    Bull Kanagawa Dent Coll; 1989 Sep; 17(2):113-23. PubMed ID: 2488881
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Intraprostatic testosterone and dihydrotestosterone. Part I: concentrations and methods of determination in men with benign prostatic hyperplasia and prostate cancer.
    van der Sluis TM; Vis AN; van Moorselaar RJ; Bui HN; Blankenstein MA; Meuleman EJ; Heijboer AC
    BJU Int; 2012 Jan; 109(2):176-82. PubMed ID: 21992222
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Androgen regulation of multidrug resistance-associated protein 4 (MRP4/ABCC4) in prostate cancer.
    Ho LL; Kench JG; Handelsman DJ; Scheffer GL; Stricker PD; Grygiel JG; Sutherland RL; Henshall SM; Allen JD; Horvath LG
    Prostate; 2008 Sep; 68(13):1421-9. PubMed ID: 18615486
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Expression of an estramustine-binding associated protein in human lung cancer cell lines.
    Bergh J; Björk P; Westlin JE; Nilsson S
    Cancer Res; 1988 Aug; 48(16):4615-9. PubMed ID: 2840198
    [TBL] [Abstract][Full Text] [Related]  

  • 58. [The prognostic significance of determining androgen receptors in prostatic cancer].
    Kushlinskiĭ NE; Bassalyk LS; Svetozarskiĭ NL; Matveev BP; Gorilovskiĭ LM; Makarova GV; Bukharkin BV; Shakhov EV; Kliuchikhin OZ
    Urol Nefrol (Mosk); 1993; (1):7-10. PubMed ID: 7941132
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Testosterone and dihydrotestosterone tissue levels in recurrent prostate cancer.
    Titus MA; Schell MJ; Lih FB; Tomer KB; Mohler JL
    Clin Cancer Res; 2005 Jul; 11(13):4653-7. PubMed ID: 16000557
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Estramustine-binding protein (EMBP).
    Högberg B
    Acta Urol Belg; 1980 Jan; 48(1):123-32. PubMed ID: 7435348
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.